Leading U.S. and S. Korean Stem Cell Companies Announce Merger
The U.S. company Stem Cell Therapy International has announced a merger with S. Korea’s Histostem.
September 25, 2009
The U.S. company Stem Cell Therapy International has announced a merger with S. Korea’s Histostem.
In collaboration with a Hong Kong company, the U.S. biotech company BioTime announces the formation of a new subsidiary, to be headquartered in China.
Researchers at Johns Hopkins University are developing new therapies based upon methods of stimulating each person’s own naturally occurring endogenous adult stem cells.
A race horse who was scheduled for retirement is instead returning to his lucrative racing career after being successfully treated with autologous adult stem cell therapy.
The XCell-Center in Germany reports positive clinical results from 45 cerebral palsy patients who were treated with autologous adult stem cells derived from bone marrow, in whom 67% improved as a result of the treatment.
Researchers at the University of Pittsburgh have received two separate NIH grants for the investigation of stem cell growth and differentiation.